Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 80

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 80
---
PTB1 program. Contra R&D expenses for the three months ended September 30, 2025 primarily offset direct program costs for DARE-LARC1, Ovaprene and DARE-HPV. Contra R&D expenses for the three months ended September 30, 2024 primarily offset direct program costs for DARE-LARC1.

38

Other income (expense) 

The increase of $0.1 million in other income (expense) for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024 was primarily due to an increase on interest earned on cash balances in the current period. 

Comparison of Nine Months Ended September 30, 2025 and 2024 (Unaudited)

The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:

Nine Months Ended September 30,Change20252024$%Revenues:Royalty revenue$6,517 $73,431 $(66,914)(91)%Total revenue6,517 73,431 (66,914)(91)%Operating expenses:General and administrative 7,186,272 7,159,979 26,293 — %Research and development 4,901,311 10,969,066 (6,067,755)(55)%Royalty expense— 7,674 (7,674)(100)%Total operating expenses12,087,583 18,136,719 (6,049,136)(33)%Loss from operations(12,081,066)(18,063,288)5,982,222 (33)%Other income (expense)Sale of royalty and milestone rights, net— 20,379,376 (20,379,376)(100)%Other income (expense), net123,510 (863,289)986,799 (114)%Net (loss) income$(11,957,556)$1,452,799 $(13,410,355)(923)%Other comprehensive (loss) income:Foreign currency translation adjustments32,843 (1,729)34,572 (2000)%Comprehensive (loss) income$(11,924,713)$1,451,070 $(13,375,783)(922)%

Revenues

Revenues for the nine months ended September 30, 2025